Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its participation in the pioneering French INSIGHT study of Alzheimer’s disease (AD). The Cytox proposal, ‘Single Nucleotide Polymorphism (SNP) Profiling as an Approach to Risk Stratification for Future Cognitive Decline in Elderly Subjective Memory Complainers’, has been reviewed and approved by the INSIGHT Scientific Committee.
INSIGHT is a study of Alzheimer’s disease and one of the first in the world to monitor healthy subjects at risk. Led by Professor Harald Hampel, AXA-UPMC Chair at Université Pierre et Marie Curie, Paris, France and Professor Bruno Dubois, Director of IM2A (Institute of Memory and Alzheimer’s Disease, located at La Pitié Salpêtrière University Hospital in Paris), and based at the ICM (Brain and Spine Institute, Paris), the study is a collaboration with Pfizer and Avid.
See the article in full at VentureBeat.com